The European Medicines Agency's CHMP has given a positive opinion recommending approval of AbbVie's upadacitinib for treating severe alopecia areata in adults and adolescents. This recommendation follows Phase 3 trial data showing significant hair regrowth and safety consistent with other uses of the drug. The final EU approval decision is expected soon, potentially offering a new treatment option for this autoimmune hair loss condition. Upadacitinib is already approved for several other immune diseases but not yet for alopecia areata in the EU.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending upadacitinib for treating adult and adolescent patients with non-segmental vitiligo, a chronic autoimmune skin disease. Th...
The JPMorgan Equity Premium Income ETF (JEPI) pays monthly distributions currently yielding about 8.3%, but the payment amount fluctuates due to its strategy of selling out-of-the-money call options, which generate premiums that depend on market vola...
The FDA has approved SKYRIZI (risankizumab-rzaa) for treating children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing i...
Shares of AbbVie, Eli Lilly, and Johnson & Johnson are reaching all-time highs, reflecting renewed investor interest in the biopharmaceutical sector. AbbVie's recent announcement to acquire Apogee Therapeutics boosted its stock by 12%. Analysts attri...
Vanguard High Dividend Yield Index Fund ETF (VYM) provides income through dividends from over 500 U.S. stocks, focusing on large, profitable companies like Broadcom and JPMorgan Chase. With a very low expense ratio of 0.04%, nearly all dividends are ...
